Home/Filings/3/0001209191-04-022341
3//SEC Filing

MPM BIOVENTURES III PARALLEL FUND 3

Accession 0001209191-04-022341

CIK 0001173657other

Filed

Apr 27, 8:00 PM ET

Accepted

Apr 28, 1:54 PM ET

Size

20.1 KB

Accession

0001209191-04-022341

Insider Transaction Report

Form 3
Period: 2004-04-28
Holdings
  • Series C Preferred Stock

    (indirect: See Footnotes)
    Exercise: $0.00From: 2004-04-28Exp: 2004-05-03Common Stock (4,282,050 underlying)
Holdings
  • Series C Preferred Stock

    (indirect: See Footnotes)
    Exercise: $0.00From: 2004-04-28Exp: 2004-05-03Common Stock (4,282,050 underlying)
Holdings
  • Series C Preferred Stock

    (indirect: See Footnotes)
    Exercise: $0.00From: 2004-04-28Exp: 2004-05-03Common Stock (4,282,050 underlying)
Holdings
  • Series C Preferred Stock

    (indirect: See Footnotes)
    Exercise: $0.00From: 2004-04-28Exp: 2004-05-03Common Stock (4,282,050 underlying)
Holdings
  • Series C Preferred Stock

    (indirect: See Footnotes)
    Exercise: $0.00From: 2004-04-28Exp: 2004-05-03Common Stock (4,282,050 underlying)
Holdings
  • Series C Preferred Stock

    (indirect: See Footnotes)
    Exercise: $0.00From: 2004-04-28Exp: 2004-05-03Common Stock (4,282,050 underlying)
Holdings
  • Series C Preferred Stock

    (indirect: See Footnotes)
    Exercise: $0.00From: 2004-04-28Exp: 2004-05-03Common Stock (4,282,050 underlying)
Holdings
  • Series C Preferred Stock

    (indirect: See Footnotes)
    Exercise: $0.00From: 2004-04-28Exp: 2004-05-03Common Stock (4,282,050 underlying)
Holdings
  • Series C Preferred Stock

    (indirect: See Footnotes)
    Exercise: $0.00From: 2004-04-28Exp: 2004-05-03Common Stock (4,282,050 underlying)
WHEELER KURT
10% Owner
Holdings
  • Series C Preferred Stock

    (indirect: See Footnotes)
    Exercise: $0.00From: 2004-04-28Exp: 2004-05-03Common Stock (4,282,050 underlying)
Footnotes (2)
  • [F1]Each share of Series C Convertible Preferred Stock will convert automatically on a 2 for 1 basis into shares of Common Stock upon the closing of Issuer's initial public offering.
  • [F2]See Form 3 filed for Luke Evnin for additional members of the joint filing. The shares are held as follows: 3,564,477 by MPM BioVentures III-QP, L.P. ("BV III QP"), 239,666 by MPM BioVentures III, L.P. ("BV III"), 69,014 by MPM Asset Management Investors 2003 BVIII, LLC ("BV AM III"), 107,651 by MPM BioVentures III Parallel Fund, L.P. (BV III PF) and 301,242 by MPM BioVentures GmbH & Co. Beteiligungs KG ("BV III KG"). MPM BioVentures III GP, L.P. ("BV III GP") and MPM BioVentures III LLC ("BV III LLC") are the direct and indirect general partners of BV III, BV III QP, BV III PF and BV III KG. Luke Evnin, Ansbert Gadicke, Nicholas Galakatos, Dennis Henner, Michael Steinmetz, Nicholas Simon, III and Kurt Wheeler are the members of BV III LLC and BV AM III. Each member of the group disclaims beneficial ownership of the securities except to the extent of its pecuniary interest therein.

Issuer

BARRIER THERAPEUTICS INC

CIK 0001173657

Entity typeother
IncorporatedDE

Related Parties

1
  • filerCIK 0001249063

Filing Metadata

Form type
3
Filed
Apr 27, 8:00 PM ET
Accepted
Apr 28, 1:54 PM ET
Size
20.1 KB